Drug intelligence / Profile preview

roseofungin

Development stage: Phase 1
Lead developer: Scientific and Production Center for Microbiology and Virology
Modality: Small Molecules
Administration: Vaginal

Overview

CanProFem-AK is an antifungal drug containing roseofungin 100 mg as the active pharmaceutical ingredient, formulated as vaginal suppositories. It is being developed for the treatment of candidiasis (fungal infections). The drug was developed at the Research and Production Center of Microbiology and Virology. A Phase 1 clinical trial has been conducted to evaluate its safety and tolerability in healthy female volunteers.

Brand names: CanProFem-AK
Other names: Roseofungin

Targets

Ergosterol

Beyond the preview

Go deeper on roseofungin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on roseofungin.

Explore the full profile